A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)

Breast

Volumn 23, Issue 5, 2014, Pages 663-669

  Fumoleau, Pierre ^a   Koch, Kevin M ^b   Brain, Etienne ^c   Lokiec, François ^c   Rezai, Keyvan ^c   Awada, Ahmad ^d   Hayward, Larry ^e   Werutsky, Gustavo ^f   Bogaerts, Jan ^f   Marréaud, Sandrine ^f   Cardoso, Fatima ^d  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b GLAXOSMITHKLINE   (United States)

^c CENTRE RENÉ HUGUENIN   (France)

^d JULES BORDET INSTITUTE   (Belgium)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f EORTC DATA CENTER   (Belgium)

Author keywords

Breast cancer; Lapatinib; Pharmacokinetics; Phase 1 clinical trials; Tamoxifen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAMOXIFEN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER FATIGUE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISEASE; STEADY STATE; SURVIVAL RATE; THROMBOCYTOPENIA; AGED; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; METASTASIS; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84908218228     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.07.003     Document Type: Article

References (30)

1. Chen W.Y., Colditz G.A. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007, 4(7):415-423.
2. Bartlett J.M., Brookes C.L., Robson T., et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. JClin Oncol 2011, 29(12):1531-1538.
3. Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29(2):217-233.
4. Cardoso F., Costa A., Norton L., et al. 1st international consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21(3):242-252.
5. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer: twenty-eight years later. JClin Oncol 1995, 13(2):513-529.
6. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
7. Gradishar W.J. Tamoxifen-what next?. Oncologist 2004, 9(4):378-384.
8. Nicholson R.I., Hutcheson I.R., Knowlden J.M., et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10(1 Pt 2):346S-354S.
9. Nicholson S., Wright C., Sainsbury J.R., et al. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. JSteroid Biochem Mol Biol 1990, 37(6):811-814.
10. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002, 71(1):67-75.
11. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 7(5):e1000279.
12. Nielsen T.O., Parker J.S., Leung S., et al. Acomparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16(21):5222-5232.
13. Cui J., Germer K., Wu T., et al. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res 2012, 72(21):5625-5634.
14. Martin L.A., Farmer I., Johnston S.R., Ali S., Marshall C., Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. JBiol Chem 2003, 278(33):30458-30468.
15. Chu I., Blackwell K., Chen S., Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005, 65(1):18-25.
16. Leary A.F., Drury S., Detre S., et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010, 16(5):1486-1497.
17. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines invitro and invivo. Mol Cancer Ther 2001, 1(2):85-94.
18. Crewe H.K., Ellis S.W., Lennard M.S., Tucker G.T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997, 53(2):171-178.
19. Smith D.A., Koch K.M., Arya N., Bowen C.J., Herendeen J.M., Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009, 67(4):421-426.
20. Bence A.K., Anderson E.B., Halepota M.A., et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005, 23(1):39-49.
21. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNatl Cancer Inst 2000, 92(3):205-216.
22. Hsieh S., Tobien T., Koch K., Dunn J. Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 2004, 18(3):285-292.
23. Gomez H.L., Doval D.C., Chavez M.A., et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. JClin Oncol 2008, 26(18):2999-3005.
24. Burris H.A., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. JClin Oncol 2005, 23(23):5305-5313.
25. Burris H.A., Taylor C.W., Jones S.F., et al. Aphase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009, 15(21):6702-6708.
26. Burstein H.J., Barry W.T., Cirrincione C., et al. Cancer Res 2010, 70(Suppl.24). abstr PD05-01.
27. Darvari R., Boroujerdi M. Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin-a comparison with tamoxifen. JPharm Pharmacol 2004, 56(8):985-991.
28. Calabrese E.J. P-glycoprotein efflux transporter activity often displays biphasic dose-response relationships. Crit Rev Toxicol 2008, 38(5):473-487.
29. Sane R.S., Buckley D.J., Buckley A.R., Nallani S.C., Desai P.B. Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug Metab Dispos 2008, 36(5):946-954.
30. Mitin T., Von Moltke L.L., Court M.H., Greenblatt D.J. Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. Drug Metab Dispos 2004, 32(8):779-782.